New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
13:21 EDTMNOVMedicNova price target lowered to $6 from $10.50 at Ladenburg
Ladenburg reduced its target on MedicNova after the company indicated that the FDA would require the company to show through a Phase III trial that its asthma treatment reduces hospitalizations. However, the firm continues to be upbeat on the stock and maintains a Buy rating.
News For MNOV From The Last 14 Days
Check below for free stories on MNOV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
19:04 EDTMNOVMedicNova announces positive interim results of MN-166 phase 2a study
MediciNova announced positive interim results of a phase 2a clinical trial of MN-166 in opioid dependence. The study is being conducted at Columbia University and the New York State Psychiatric Institute and led by Dr. Sandra Comer, Professor of Neurobiology. The interim analysis was performed after the first seven patients had completed the study, which required a 6-week stay on the inpatient unit. MN-166 demonstrated a number of beneficial effects on the subjective, analgesic, and reinforcing effects of oxycodone. MN-166 significantly decreased the craving for heroin, cocaine, and tobacco. MN-166 also decreased the positive subjective effects of oxycodone measured by mean responses to statements such as "I Feel High" and "I Liked the Dose." MN-166 also enhanced the analgesic effects of oxycodone. MN-166 reduced the sum score on the McGill Pain Questionnaire, reduced the mean rating on the Painful scale, and reduced the mean rating on the Bothersome scale. Finally, MN-166 decreased the reinforcing effects of oxycodone.
August 11, 2014
19:03 EDTMNOVMedicNova receives notice of allowance for new patent covering MN-001, MN-002
MediciNova announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 and MN-002 for the treatment of nonalcoholic fatty liver disease. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than December 2032. The allowed claims cover a method of treating nonalcoholic fatty liver disease and a method of reducing liver inflammation in nonalcoholic fatty liver disease using MN-001 or MN-002. The allowed claims cover oral administration, including tablets and capsules, as well as liquid dosage forms.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use